Skip to main content
Equibles
SBC logo

SBC · SBC Medical Group Holdings Inc · Metrics

Track SBC — free

Use SBC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SBC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$5.69 +0.24 (+4.40%) At close · Oct 29 Q2 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$573.89M
Shares
102.85M
Volume · Oct 29 258.97K Avg daily vol (3M) 190.22K

SBC metrics

99 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$5.69
Market cap
$573.89M

Price action

20 metrics
Price change (1W)
+0.0%
Price change (30D)
+15.2%
Price change (3M)
+87.2%
Price change (6M)
+72.4%
Price change (YTD)
+32.0%
Price change (1Y)
+68.3%
Trailing year
Price change (5Y)
—
52-week high
$5.69
52-week low
$2.87
Change from 52-week high
+0.0%
Change from 52-week low
+98.3%
Annualized volatility
55.3%
Annualized volatility (3M)
57.3%
Beta
0.8
RSI (14D)
63.1
Price vs SMA 50
+17.7%
Price vs SMA 200
+45.7%
Avg volume (3M)
190,219
Relative volume
1.4
Average dollar volume
$870,803

Company

3 metrics
Sector
Industrials
Industry
Consulting Services
Shares outstanding
102.85M

Valuation

12 metrics
P / E (TTM)
11.9
Trailing earnings · reciprocal yield 8.4%
PEG ratio
0.0
EV / revenue
2.4×
reciprocal yield 41.0%
EV / EBITDA
6.2×
reciprocal yield 16.1%
EV / EBIT
6.5×
reciprocal yield 15.3%
P / sales
3.3×
reciprocal yield 30.5%
P / book
2.2
reciprocal yield 46.0%
FCF yield
10.8%
TTM · current market cap
Buyback yield
0.5%
P / FCF
9.3
reciprocal yield 10.8%
P / operating cash flow
9.1
reciprocal yield 10.9%
Earnings yield
8.5%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
1.3×
reciprocal yield 76.5%
EV / revenue historical average (5Y)
1.3×
reciprocal yield 76.5%
EV / EBIT historical average (3Y)
3.7×
reciprocal yield 27.3%
EV / EBIT historical average (5Y)
3.7×
reciprocal yield 27.3%
EV / EBITDA historical average (3Y)
3.5×
reciprocal yield 28.8%
EV / EBITDA historical average (5Y)
3.5×
reciprocal yield 28.8%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.5%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-13
Last earnings
2026-08-13

Profitability

9 metrics
Gross margin
71.9%
Operating margin
37.3%
Trailing 12 months
Net margin
28.0%
Gross profit (TTM)
$125.86M
Operating profit (TTM)
$65.41M
Net income (TTM)
$49.04M
Trailing 12 months
Diluted EPS (TTM)
$0.48
FCF margin
35.3%
Effective tax rate
33.5%

Per share

11 metrics
Revenue per diluted share (TTM)
$1.71
Gross profit per diluted share (TTM)
$1.23
Operating profit per diluted share (TTM)
$0.64
EBITDA per diluted share (TTM)
$0.67
Net income per diluted share (TTM)
$0.48
Operating cash flow per diluted share (TTM)
$0.61
Free cash flow per diluted share (TTM)
$0.60
Capital expenditures per diluted share (TTM)
$0.01
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$2.42

Growth

11 metrics
Revenue growth YoY
+13.4%
Year over year
Net income growth YoY
+335.0%
Revenue (TTM)
$175.17M
Trailing 12 months
EPS growth YoY
+400.0%
Shares change YoY
-0.9%
Year over year · fewer shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
18.6%
Return on assets
12.1%
Debt / equity
0.1
Current ratio
3.3
EBITDA (TTM)
$68.63M
Free cash flow (TTM)
$61.77M
Quick ratio
3.3
Interest coverage
194.9
Net debt / EBITDA
-2.1
Return on invested capital
37.2%
Trailing 12 months
Net cash
$146.86M
Latest balance sheet
Cash & equivalents
$184.31M
Total assets
$406.66M
Total debt
$37.75M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$62.82M
Capital expenditures (TTM)
$1.05M
R&D (TTM)
—
SG&A (TTM)
$60.45M
Stock compensation (TTM)
$7,854
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
74
13F filer change QoQ
+4
Institutional ownership
8.3%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
0.4%
Private-fund adviser ownership
0.4%
Active holders' share change QoQ
+669.4%
Holder tenure
3.2
Price vs estimated holder cost
-13.7%

Ownership (registered funds)

1 metrics
Index-fund ownership
1.2%

Short interest

3 metrics
Short interest
0.7%
Latest settlement · 3.9 days to cover
Days to cover
3.9d
Short-squeeze score
55 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1930313 CUSIP 73245B107 13F (30d) 11 filings 11 filers Visit website Investor relations